Anavex Life Sciences Corp (AVXL)

[Biostockclub]

Company never said Ariana would be used for PK/PD.
I never said it would either.

I'm suggesting Ariana will be used to plan for the ph3 trial candidates. It's a debatable issue so let us wait and see?

And, if they are 32 old Australian people (with very little variation) to you, that underscores the need for computational edges to differentiate in ways which are not apparent to you. That is the What!, in answer to your "So what?" question. Emphatically, to make apparently homogeneous people, robustly, and sublimely, evidently, unique.

Really, no trial which has been run without the adaptive open label design could have ever provided this saving grace: the opportunity to look under the hood for hidden correlations.

Peace,
Bio